Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Antibody (T cell) probably leads to lower failure of reversal of acute rejection compared with steroid (stratified by antibody type) (moderate certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Antibody (T cell) showed no clear difference in recurrent rejection compared with steroid (stratified by antibody type) (moderate certainty).
1 finding from 1 review
Graft loss or death with a functioning graft · kidney transplant recipients: first rejection episode
Antibody (T cell) showed no clear difference in graft loss or death with a functioning graft compared with steroid (stratified by antibody type) (low certainty).
1 finding from 1 review
Graft loss censored for death · kidney transplant recipients: first rejection episode
Antibody (T cell) showed no clear difference in graft loss censored for death compared with steroid (stratified by antibody type) (low certainty).
1 finding from 1 review
Death · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) changes death compared with steroid (stratified by antibody type) (very low certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) changes treatment adverse events: fever, chill, or malaise after drug… compared with steroid (stratified by antibody type) (very low certainty).
1 finding from 1 review
Graft loss censored for death · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) + steroid changes graft loss censored for death compared with steroid alone (very low certainty).
1 finding from 1 review
Death · kidney transplant recipients: first rejection episode
Antibody (T cell) + steroid showed no clear difference in death compared with steroid alone (low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Antibody (T cell) + steroid showed no clear difference in failure of reversal of acute rejection episode compared with steroid alone (low certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Antibody (T cell) + steroid showed no clear difference in recurrent rejection compared with steroid alone (low certainty).
1 finding from 1 review
Graft loss or death with a functioning graft · kidney transplant recipients: first rejection episode
It is very uncertain whether antibody (T cell) + steroid changes graft loss or death with a functioning graft compared with steroid alone (very low certainty).
1 finding from 1 review
Mortality Mortality at latest · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in mortality Mortality at latest compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Acute rejection Acute rejection grade 3A or more verified by biopsy · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in acute rejection Acute rejection grade 3A or more verified by biopsy compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Infection Number of participants diagnosed with infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in infection Number of participants diagnosed with infection compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
CMV infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Cancer · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cancer Number of participants diagnosed with cancer compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review